Positive Results From Phase 3 Trial For Glioblastoma Patients

Northwest Biotherapeutics reported that in its Phase III clinical trial, median survival and the “long tail” of extended survival increased in newly diagnosed and recurrent glioblastoma brain cancer patients treated with DCVax®-L.

The trial results published by The JAMA Network on November 17, 2022, have met both the primary and the secondary endpoints under the Statistical Analysis Plan for the trial.

The Company believes this is the first time in nearly 20 years that a Phase III trial of a systemic treatment has shown such survival extension in newly diagnosed glioblastoma and the first time in almost 30 years that a Phase III trial of any treatment has shown such survival extension in recurrent glioblastoma.